These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28531205)

  • 21. Burden of Disease of Human Papillomavirus (HPV): Hospitalizations in the Marche and Veneto Regions. An observational study.
    Mennini FS; Fabiano G; Marcellusi A; Sciattella P; Saia M; Cocchio S; Baldo V
    Clin Drug Investig; 2018 Feb; 38(2):173-180. PubMed ID: 29081028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.
    Thomas TL
    Pediatr Nurs; 2008; 34(5):429-31. PubMed ID: 19051848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom.
    Woodhall SC; Jit M; Cai C; Ramsey T; Zia S; Crouch S; Birks Y; Newton R; Edmunds WJ; Lacey CJ
    Sex Transm Dis; 2009 Aug; 36(8):515-21. PubMed ID: 19543143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study.
    Hillemanns P; Breugelmans JG; Gieseking F; Bénard S; Lamure E; Littlewood KJ; Petry KU
    BMC Infect Dis; 2008 Jun; 8():76. PubMed ID: 18518976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the epidemiology and morbidity burden associated with human papillomavirus in Israel: accounting for CIN1 and genital warts in addition to CIN2/3 and cervical cancer.
    Shavit O; Raz R; Stein M; Chodick G; Schejter E; Ben-David Y; Cohen R; Arbel D; Shalev V
    Appl Health Econ Health Policy; 2012 Mar; 10(2):87-97. PubMed ID: 22201263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age-based programs for vaccination against HPV.
    Elbasha EH; Dasbach EJ; Insinga RP; Haupt RM; Barr E
    Value Health; 2009; 12(5):697-707. PubMed ID: 19490561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates.
    Ong KJ; Checchi M; Burns L; Pavitt C; Postma MJ; Jit M
    Sex Transm Infect; 2019 Feb; 95(1):28-35. PubMed ID: 30674687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The costs of managing genital warts in the UK by devolved nation: England, Scotland, Wales and Northern Ireland.
    Coles VA; Chapman R; Lanitis T; Carroll SM
    Int J STD AIDS; 2016 Jan; 27(1):51-7. PubMed ID: 25681263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment patterns and associated costs for genital warts in Italy.
    Merito M; Largeron N; Cohet C; Timelli L; Boselli F; Matteelli A; Naldi L; Vittori G
    Curr Med Res Opin; 2008 Nov; 24(11):3175-83. PubMed ID: 18851777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia.
    Ezat SW; Aljunid S
    Asian Pac J Cancer Prev; 2010; 11(4):943-51. PubMed ID: 21133606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The annual costs associated with human papillomavirus types 6, 11, 16, and 18 infections in Finland.
    Herse F; Reissell E
    Scand J Infect Dis; 2011 Mar; 43(3):209-15. PubMed ID: 21171829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of HPV vaccination in Belize.
    Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
    Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic burden of HPV9-related diseases: a real-world cost analysis from Italy.
    Mennini FS; Fabiano G; Favato G; Sciattella P; Bonanni P; Pinto C; Marcellusi A
    Eur J Health Econ; 2019 Aug; 20(6):829-840. PubMed ID: 30900047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
    Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
    Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quadrivalent human papillomavirus vaccine.
    Barr E; Tamms G
    Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Burden of human papillomavirus-related cervical disease in the extended middle East and north Africa-a comprehensive literature review.
    Seoud M
    J Low Genit Tract Dis; 2012 Apr; 16(2):106-20. PubMed ID: 22371041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.